Demicheli R, Abbattista A, Miceli R, Valagussa P, Bonadonna G: Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: further support about the concept of tumor dormancy. Breast Cancer Res Treat. 1996, 41: 177-185. 10.1007/BF01807163.
Article
CAS
PubMed
Google Scholar
Carter CL, Allen C, Henson DE: Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989, 63: 181-187. 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H.
Article
CAS
PubMed
Google Scholar
Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D: Molecular portraits of human breast tumours. Nature. 2000, 406: 747-752. 10.1038/35021093.
Article
CAS
PubMed
Google Scholar
Park YH, Lee SJ, Cho EY, Choi YL, Lee JE, Nam SJ, Yang JH, Shin JH, Ko EY, Han BK, Ahn JS, Im YH: Clinical relevance of TNM staging system according to breast cancer subtypes. Ann Oncol. 2011, 22: 1554-1560. 10.1093/annonc/mdq617.
Article
CAS
PubMed
Google Scholar
Hernandez-Aya LF, Chavez-MacGregor M, Lei X, Meric-Bernstam F, Buchholz TA, Hsu L, Sahin AA, Do KA, Valero V, Hortobagyi GN, Gonzalez-Angulo AM: Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. J Clin Oncol. 2011, 29: 2628-2634. 10.1200/JCO.2010.32.1877.
Article
PubMed
PubMed Central
Google Scholar
Seo S, Hatano E, Higashi T, Hara T, Tada M, Tamaki N, Iwaisako K, Ikai I, Uemoto S: Fluorine-18 fluorodeoxyglucose positron emission tomography predicts tumor differentiation, P-glycoprotein expression, and outcome after resection in hepatocellular carcinoma. Clin Cancer Res. 2007, 13: 427-433. 10.1158/1078-0432.CCR-06-1357.
Article
CAS
PubMed
Google Scholar
Cerfolio RJ, Bryant AS, Ohja B, Bartolucci AA: The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival. J Thorac Cardiovasc Surg. 2005, 130: 151-159. 10.1016/j.jtcvs.2004.11.007.
Article
PubMed
Google Scholar
Ueda S, Kondoh N, Tsuda H, Yamamoto S, Asakawa H, Fukatsu K, Kobayashi T, Yamamoto J, Tamura K, Ishida J, Abe Y, Yamamoto M, Mochizuki H: Expression of centromere protein F (CENP-F) associated with higher FDG uptake on PET/CT, detected by cDNA microarray, predicts high-risk patients with primary breast cancer. BMC Cancer. 2008, 8: 384-10.1186/1471-2407-8-384.
Article
PubMed
PubMed Central
Google Scholar
Palaskas N, Larson SM, Schultz N, Komisopoulou E, Wong J, Rohle D, Campos C, Yannuzzi N, Osborne JR, Linkov I, Kastenhuber ER, Taschereau R, Plaisier SB, Tran C, Heguy A, Wu H, Sander C, Phelps ME, Brennan C, Port E, Huse JT, Graeber TG, Mellinghoff IK: 18F-fluorodeoxy-glucose positron emission tomography marks MYC-overexpressing human basal-like breast cancers. Cancer Res. 2011, 71: 5164-5174. 10.1158/0008-5472.CAN-10-4633.
Article
CAS
PubMed
PubMed Central
Google Scholar
Basu S, Chen W, Tchou J, Mavi A, Cermik T, Czerniecki B, Schnall M, Alavi A: Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Cancer. 2008, 112: 995-1000. 10.1002/cncr.23226.
Article
CAS
PubMed
Google Scholar
Shimoda W, Hayashi M, Murakami K, Oyama T, Sunagawa M: The relationship between FDG uptake in PET scans and biological behavior in breast cancer. Breast Cancer. 2007, 14: 260-268. 10.2325/jbcs.14.260.
Article
PubMed
Google Scholar
Mavi A, Cermik TF, Urhan M, Puskulcu H, Basu S, Yu JQ, Zhuang H, Czerniecki B, Alavi A: The effects of estrogen, progesterone, and C-erbB-2 receptor states on 18F-FDG uptake of primary breast cancer lesions. J Nucl Med. 2007, 48: 1266-1272. 10.2967/jnumed.106.037440.
Article
CAS
PubMed
Google Scholar
Moeder CB, Giltnane JM, Harigopal M, Molinaro A, Robinson A, Gelmon K, Huntsman D, Camp RL, Rimm DL: Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its implications for tissue microarray–based assessment of outcome. J Clin Oncol. 2007, 25: 5418-5425. 10.1200/JCO.2007.12.8033.
Article
PubMed
Google Scholar
American Joint Committee on Cancer (AJCC): AJCC Cancer Staging Manual. 7th edition. Edited by Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. New York: Springer; 2010.
Harrell FE, Lee KL, Mark DB: Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996, 15: 361-387. 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4.
Article
PubMed
Google Scholar
Han W, Kang SY, Korean Breast Cancer Society: Relationship between age at diagnosis and outcome of premenopausal breast cancer: age less than 35 years is a reasonable cut-off for defining young age-onset breast cancer. Breast Cancer Res Treat. 2010, 119: 193-200. 10.1007/s10549-009-0388-z.
Article
PubMed
Google Scholar
The R Project for Statistical Computing. http://www.r-projet.org.
De Cicco C, Gilardi L, Botteri E, Fracassi SL, Di Dia GA, Botta F, Prisco G, Lombardo D, Rotmensz N, Veronesi U, Paganelli G: Is [18F] fluorodeoxyglucose uptake by the primary tumor a prognostic factor in breast cancer?. Breast. 2013, 22: 39-43. 10.1016/j.breast.2012.05.009.
Article
PubMed
Google Scholar
Inoue T, Yutani K, Taguchi T, Tamaki Y, Shiba E, Noguchi S: Preoperative evaluation of prognosis in breast cancer patients by [18F]2-deoxy-2-fluoro-d-glucose-positron emission tomography. J Cancer Res Clin Oncol. 2004, 130: 273-278. 10.1007/s00432-003-0536-5.
Article
PubMed
Google Scholar
Ueda S, Tsuda H, Asakawa H, Shigekawa T, Fukatsu K, Kondo N, Yamamoto M, Hama Y, Tamura K, Ishida J, Abe Y, Mochizuki H: Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer. Jpn J Clin Oncol. 2008, 38: 250-258. 10.1093/jjco/hyn019.
Article
PubMed
Google Scholar
Vander Heiden MG, Cantley LC, Thompson CB: Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009, 324: 1029-1033. 10.1126/science.1160809.
Article
CAS
PubMed
PubMed Central
Google Scholar
Schieber MS, Chandel NS: ROS links glucose metabolism to breast cancer stem cell and EMT phenotype. Cancer Cell. 2013, 23: 265-267. 10.1016/j.ccr.2013.02.021.
Article
CAS
PubMed
Google Scholar
Levine AJ, Puzio-Kuter AM: The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science. 2010, 330: 1340-1344. 10.1126/science.1193494.
Article
CAS
PubMed
Google Scholar
Dang CV: Links between metabolism and cancer. Genes Dev. 2012, 26: 877-890. 10.1101/gad.189365.112.
Article
CAS
PubMed
PubMed Central
Google Scholar
Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B, Desmedt C, Ignatiadis M, Sengstag T, Schütz F, Goldstein DR, Piccart M, Delorenzi M: Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 2008, 10: R65-10.1186/bcr2124.
Article
PubMed
PubMed Central
Google Scholar
Yau C, Sninsky J, Kwok S, Wang A, Degnim A, Ingle JN, Gillett C, Tutt A, Waldman F, Moore D, Esserman L, Benz CC: An optimized five-gene multi-platform predictor of hormone receptor negative and triple negative breast cancer metastatic risk. Breast Cancer Res. 2013, 15: R103-10.1186/bcr3567.
Article
PubMed
PubMed Central
Google Scholar
Koo HR, Park JS, Kang KW, Cho N, Chang JM, Bae MS, Kim WH, Lee SH, Kim MY, Kim JY, Seo M, Moon WK: 18F-FDG uptake in breast cancer correlates with immunohistochemically defined subtypes. Eur Radiol. 2014, 24: 610-618. 10.1007/s00330-013-3037-1.
Article
PubMed
Google Scholar